Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited’s 2025 Annual General Meeting, held in Melbourne, revealed key shareholder voting outcomes on several resolutions. Notably, the ‘second strike’ against the Remuneration Report was recorded, triggering a conditional Spill Resolution, which was ultimately not carried. The meeting also saw the election of directors and approval of performance share units, reflecting the company’s ongoing governance and strategic initiatives.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$265.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company based in Melbourne, Australia, specializing in the development and manufacturing of innovative medicines. The company focuses on providing life-saving therapies for people with rare and serious diseases, particularly in the areas of immunology, hematology, and respiratory health.
Average Trading Volume: 1,206,320
Technical Sentiment Signal: Sell
Current Market Cap: A$103.1B
See more insights into CSL stock on TipRanks’ Stock Analysis page.